Recently, an increasing number of studies have evaluated the relative prognostic impact of IDH mutations and the clinical outcome of gliomas [16]–[25], with conflicting results due to the relatively small sample sizes in the studies. The gene discussed is IDH1; the disease is central nervous system cancer.